Ibrutinib, an oral inhibitor of Bruton tyrosine kinase (BTK), has shown strong activity in relapsing patients with Chronic Lymphocytic Leukemia (CLL) and MCL. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.